Genentech receives FDA approval for cancer treatment
Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults.
STAT6d
Genentech, a biotech with a storied past, confronts new turbulence in the present
For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...
FiercePharma8d
Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...
STAT5d
The essential biotech updates of the day
AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...
Managed Healthcare Executive8d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...
pharmaphorum10d
FDA grants fast review for Genentech's bladder cancer drug atezolizumab
The US Food and Drug Administration (FDA) has granted priority review to Genentech's advanced bladder cancer drug, atezolizumab. The Roche unit said yesterday that the FDA is set to make a ...
Business Wire9d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Medscape6d
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...
CEO exits from company with 2nd-largest biotech IPO this year
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
MarketWatch9d
Genentech Receives FDA Approval for Cancer Treatment
Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The treatment, called Tecentriq Hybreza ...
FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (RHHBY), said Thursday that the U.S. Food and Drug Administration has approved Tecentriq ...
Yahoo Finance9d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
September 12, 2024--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ...